Trial Profile
Randomized, Double-blinded, Placebo Controlled, Multicenter, Phase III Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 Apr 2024
Price :
$35
*
At a glance
- Drugs Adebrelimab (Primary) ; Carboplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 13 May 2022 Primary endpoint (Duration of Overall Survival (OS)) has been met, according to Results published in the Lancet Oncology.
- 13 May 2022 Results assessing the efficacy and safety of adebrelimab, published in the Lancet Oncology.
- 14 Apr 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.